Resistance to bortezomib in breast cancer cells that downregulate Bim through FOXA1 O-GlcNAcylation
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Resistance to bortezomib in breast cancer cells that downregulate Bim through FOXA1 O-GlcNAcylation
Authors
Keywords
-
Journal
JOURNAL OF CELLULAR PHYSIOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-02-22
DOI
10.1002/jcp.28376
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- O-GlcNAc elevation through activation of the hexosamine biosynthetic pathway enhances cancer cell chemoresistance
- (2018) Yubo Liu et al. Cell Death & Disease
- Protein O-GlcNAcylation: emerging mechanisms and functions
- (2017) Xiaoyong Yang et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma
- (2015) Tadeusz Robak et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis
- (2014) S. Chen et al. BLOOD
- Linking the activity of bortezomib in multiple myeloma and autoimmune diseases
- (2014) Zdeněk Škrott et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- O-GlcNAc Transferase Integrates Metabolic Pathways to Regulate the Stability of c-MYC in Human Prostate Cancer Cells
- (2013) H. M. Itkonen et al. CANCER RESEARCH
- Dynamic O-GlcNAcylation and its roles in the cellular stress response and homeostasis
- (2013) Jennifer A. Groves et al. CELL STRESS & CHAPERONES
- Hyper-O-GlcNAcylation Is Anti-apoptotic and Maintains Constitutive NF-κB Activity in Pancreatic Cancer Cells
- (2013) Zhiyuan Ma et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- O-GlcNAcylation-Inducing Treatments Inhibit Estrogen Receptor α Expression and Confer Resistance to 4-OH-Tamoxifen in Human Breast Cancer-Derived MCF-7 Cells
- (2013) Shahzina Kanwal et al. PLoS One
- FOXA1 is an independent prognostic marker for ER-positive breast cancer
- (2011) Rutika J. Mehta et al. BREAST CANCER RESEARCH AND TREATMENT
- Bortezomib Enhances the Efficacy of Fulvestrant by Amplifying the Aggregation of the Estrogen Receptor, Which Leads to a Proapoptotic Unfolded Protein Response
- (2011) Y. Ishii et al. CLINICAL CANCER RESEARCH
- Bortezomib Induces Nuclear Translocation of I B Resulting in Gene-Specific Suppression of NF- B-Dependent Transcription and Induction of Apoptosis in CTCL
- (2011) A. Juvekar et al. MOLECULAR CANCER RESEARCH
- Inhibition of proteasome deubiquitinating activity as a new cancer therapy
- (2011) Pádraig D'Arcy et al. NATURE MEDICINE
- Phase II Study of Bortezomib and Pegylated Liposomal Doxorubicin in the Treatment of Metastatic Breast Cancer
- (2010) William J. Irvin et al. Clinical Breast Cancer
- FOXA1 is a key determinant of estrogen receptor function and endocrine response
- (2010) Antoni Hurtado et al. NATURE GENETICS
- Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study
- (2008) A Awada et al. BRITISH JOURNAL OF CANCER
- IFN- and Bortezomib Overcome Bcl-2 and Mcl-1 Overexpression in Melanoma Cells by Stimulating the Extrinsic Pathway of Apoptosis
- (2008) G. B. Lesinski et al. CANCER RESEARCH
- Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells
- (2008) Changyou Li et al. MOLECULAR CANCER THERAPEUTICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started